The Global Peptide Therapeutics Industry is experiencing a remarkable surge, fueled by its growing significance in the pharmaceutical landscape. A recent market analysis reveals the industry’s current valuation at US$38 billion in 2023. Looking ahead, it’s projected to reach a staggering US$106 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.8%. This upward trajectory underscores the escalating significance and potential of peptide therapeutics within the global pharmaceutical landscape. The industry’s growth is fueled by cutting-edge research, innovation, and a growing demand for effective and precision-targeted treatment options.
Peptide medicines have been used to treat metabolic illnesses for more than a century. Peptide drugs offer numerous advantages over tiny chemical compounds, resulting in huge demand across geographies.
Here are some of the key advantages of the Global Peptide Therapeutics Industry :
- They are highly specific and have fewer side effects than chemical compounds.
- They can be delivered orally, nasally, or topically, which makes them more convenient to administer.
- They are more stable in the body and have a longer half-life than chemical compounds.
Further, peptide therapeutics can be a preferred alternative to small molecule and biological therapeutics. All of these factors have led to an upsurge in research and investments in peptide drug recovery over the last ten years and are expected to bode well for the future prospects of the market.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1038
Again, surging incidences of metabolic disorders and the high prevalence of cancer propel the demand for investments in research and development activities in the field of peptide therapies. These illnesses are the prime cause of death and disability all over the world. As a result, there is a greater demand for the development of peptide therapeutics. Peptide-based drug delivery for cancer cells coupled with enhancements in the next-generation therapeutics will presumably supplement the market expansion of peptide therapeutics. In addition to this, there’s a rise in interest in therapeutic peptide research due to commercial reasons. Thus, it is presumed that peptide drug recovery will play a crucial role in the healthcare industry.
“Heightened application of peptides in the treatment of diabetes and cancer will likely augment the sales of peptide therapeutics in the global market over the forecast period,” says an FMI analyst.
Global Peptide Therapeutics Industry Key Takeaways:
- The popularity of oral peptide-based drugs generates attractive market opportunities.
- Peptide-based therapeutics will continue to gain momentum in Cosmeceuticals.
- Government support to aid market growth in North America.
- India will offer various lucrative opportunities to the peptide therapeutics industry.
- Based on the route of administration, the parenteral route segment will continue to gain preference during the assessment period.
Competitive Landscape from the Global Peptide Therapeutics Industry :
Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., Ipsen S.A, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd., among others, are some of the major players in the peptide therapeutics industry that are profiled in the full version of the report.
In a moderately competitive market, major players are concentrating on market expansion activities. These organizations are engaging in distribution agreements, white space exploration, and collaborative ventures. The more established businesses are focusing on working with local players to expand their production capacities and improve their regional presence.
More Insights into the Global Peptide Therapeutics Industry Report
In its latest report, FMI offers an unbiased analysis of the global peptide therapeutics industry, providing historical data from 2014 to 2021 and forecast statistics for 2022 to 2025. To understand the global market potential, growth, and range, the market is segmented based on application (cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, other applications), route of administration (parenteral route of administration, mucosal route of administration, oral route of administration, transdermal route of administration), drug type (branded drugs, generic/ biosimilar drugs), and region.
According to the latest FMI reports, based on region, the peptide therapeutics market in North America is expected to dominate the market over the forecast period. A surge in government investments as well as an increase in industry spending on research and development activities in peptide therapeutics is driving the regional market growth. This market is further supported by the target market expansion in the United States. Owing to the high prevalence of cancer along with increasing research and development activities, the U.S. peptide therapeutics market is expected to witness impressive growth over the forecast period.
In India, the peptide therapeutics industry is anticipated to gain many profitable future prospects. The rising adoption of synthetic peptide drugs in India is likely to propel the market growth in this region. Rising incidences of chronic illnesses and an aging population also contribute to market growth. Based on the segmentation, based on the route of administration, the parenteral route will continue to gain momentum over the forecast period.
Access Exclusive Market Insights – Purchase Now
https://www.futuremarketinsights.com/checkout/1038
Global Peptide Therapeutics Industry Key Segments:
By Application:
- Cancer
- Cardiovascular Diseases
- Central Nervous Systems
- Metabolic Disorders
- Infections
- Hematological Disorders
- Gastrointestinal Disorders
- Dermatology
- Respiratory Disorders
- Acromegaly
- Other Applications
By Route of Administration:
- Parenteral Route of Administration
- Mucosal Route of Administration
- Oral Route of Administration
- Transdermal of Route Administration
By Drug Type:
- Branded Drugs
- Generic/Biosimilar Drugs
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
